Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model

Blood

Volumn 130, Issue 8, 2017, Pages 1052-1061

  Slichter, Sherrill J ^a,b   Pellham, Esther ^a   Bailey, S Lawrence ^a   Christoffel, Todd ^a   Gettinger, Irena ^a   Gaur, Lakshmi ^c   Latchman, Yvette ^d   Nelson, Karen ^a   Bolgiano, Doug ^a  

^a BloodWorks Northwest   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Titan Molecular Laboratories   (United States)

^d Etubics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; LYMPHOCYTE ANTIGEN; ALLOANTIGEN; ANTIBODY;

ALLOIMMUNE PLATELET REFRACTORINESS; ALLOIMMUNIZATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; FILTRATION; GAMMA IRRADIATION; LEUKOFILTRATION; MIRASOL PATHOGEN REDUCTION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGEN REDUCTION SYSTEM; PRIORITY JOURNAL; REFRACTORY PERIOD; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; ULTRAVIOLET B RADIATION; ANIMAL; ANIMAL MODEL; BLOOD TRANSFUSION; CYTOLOGY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LEUKOCYTE; METABOLISM; MICROBIAL VIABILITY; SURVIVAL ANALYSIS; THROMBOCYTE; THROMBOCYTE RICH PLASMA;

ANIMALS; ANTIBODIES; BLOOD PLATELETS; BLOOD TRANSFUSION; DOGS; FILTRATION; IMMUNE TOLERANCE; IMMUNIZATION; ISOANTIGENS; LEUKOCYTES; MICROBIAL VIABILITY; MODELS, ANIMAL; PLATELET-RICH PLASMA; SURVIVAL ANALYSIS;

EID: 85028471708     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-07-726901     Document Type: Article

References (28)

1. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26): 1861-1870.
2. Slichter SJ, Abrams K, Gettinger I, et al. Ultraviolet B irradiation in the prevention of alloimmunization in a dog platelet transfusion model. Transfusion. 2016;56(6):1340-1347.
3. Slichter SJ, Fish D, Abrams VK, Gaur L, Nelson K, Bolgiano D. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model. Blood. 2005;105(2):847-854.
4. Slichter SJ, Abrams K, Bailey SL, et al. Further studies to evaluate methods of leucoreduction to prevent alloimmune platelet refractoriness and induce tolerance in a dog platelet transfusion model. Vox Sang. 2016;111(1):62-70.
5. Semple JW, Speck ER, Cosgrave D, Lazarus AH, Blanchette VS, Freedman J. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood. 1999;93(2): 713-720.
6. Ledent E, Semple JW, Berlin G. White blood cell subsets in buffy coat-derived platelet concentrates: The effect of pre- and poststorage filtration. Vox Sang. 2000;79(4):235-241.
7. Kao KJ. Effects of leukocyte depletion and UVB irradiation on alloantigenicity of major histocompatibility complex antigens in platelet concentrates: A comparative study. Blood. 1992; 80(11):2931-2937.
8. Slichter SJ. Understanding the effects of different types of white cells on patient's responses to transfusion: Immunization versus tolerization. Vox Sang. 2002;83(Suppl 1):421-424.
9. Goodrich RP, Edrich RA. LI J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci. 2006;35(1):5-17.
10. Snyder EL, Whitley P, Kingsbury T, Miripol J, Tormey CA. In vitro and in vivo evaluation of a whole blood platelet-sparing leukoreduction filtration system. Transfusion. 2010;50(10): 2145-2151.
11. Weiden PL, Storb R, Slichter S, Warren RP, Sale GE. Effect of six weekly transfusions on canine marrow grafts: Tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol. 1976;117(1): 143-150.
12. Belcher EH, Berlin NI, Eernisse JG, et al; Panel on Diagnostic Application of Radioisotopes in Hematology, International Committee for Standardization in Hematology. Recommended methods for radioisotope platelet survival studies. Blood. 1977;50(6):1137-1144.
13. Lewis DC, McVey DS, Shuman WS, Muller WB. Development and characterization of a flow cytometric assay for detection of platelet-bound immunoglobulin G in dogs. Am J Vet Res. 1995; 56(12):1555-1558.
14. Gaur LK, Shewey LM, Sharkey-Mathis D, Nepom GT. Transcriptional regulatory elements in nonhuman primate MHC-DQB genes. Transgenics. 1994;1:267-276.
15. Gaur LK, Nepom GT, Snyder KE, et al. MHC-DRB allelic sequences incorporate distinct intragenic trans-specific segments. Tissue Antigens. 1997; 49(4):342-355.
16. Gaur LK, Nepom GT. Ancestral major histocompatibility complex DRB genes beget conserved patterns of localized polymorphisms. Proc Natl Acad Sci USA. 1996;93(11): 5380-5383.
17. Waanders MM, Roelen DL, Brand A, Claas FH. The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. Transfus Med Rev. 2005;19(4): 281-287.
18. Claas FH, Roelen DL, van Rood JJ, Brand A. Modulation of the alloimmune response by blood transfusions. Transfus Clin Biol. 2001;8(3): 315-317.
19. Sonntag KC, Emery DW, Yasumoto A, et al. Tolerance to solid organ transplants through transfer of MHC class II genes. J Clin Invest. 2001;107(1):65-71.
20. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag22/2 gamma c2/2 double knockout mice. Transfusion. 2006; 46(9):1553-1560.
21. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: Pathophysiology, significance, prevention and management. Tissue Antigens. 2012;79(4): 237-245.
22. Curtis BR, McFarland JG. Human platelet antigens-2013. Vox Sang. 2014;106(2):93-102.
23. Kools A, Collins J, Aster RH. Studies of the ABO antigens of human platelets. Transfusion. 1981; 21(5):615.
24. Sowemimo-Coker SO, Kim A, Tribble E, Brandwein HJ, Wenz B. White cell subsets in apheresis and filtered platelet concentrates. Transfusion. 1998;38(7):650-657.
25. Read EJ, Kodis C, Carter CS, Leitman SF. Viability of platelets following storage in the irradiated state. A pair-controlled study. Transfusion. 1988;28(5):446-450.
26. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-4114.
27. Nelson KA, Warner P, Latchman Y, Slichter SJ. Immunomodulatory effects of transfusion [abstract]. Blood. 2015;126(23). Abstract 1144.
28. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45(8): 1335-1341.